Biohaven doses first patient with its novel trop-2 directed antibody drug conjugate (adc) bhv-1510 in advanced or metastatic epithelial tumors

-bhv-1510 is a novel trophoblast cell surface antigen-2 (trop-2) directed antibody drug conjugate (adc) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other trop-2 adcs currently in development, and synergistic affects when combined with anti-pd1 therapy -biohaven also entered into a clinical supply agreement with regeneron to study the combination of bhv-1510 with regeneron's anti-pd-1 libtayo® (cemiplimab-rwlc) in the phase 1/2 clinical trial -malignancies of epithelial tissue account for the vast majority of all cancers and the advanced  or metastatic forms of these carcinomas represent an urgent unmet medical need new haven, conn. , may 29, 2024 /prnewswire/ -- biohaven ltd.
REGN Ratings Summary
REGN Quant Ranking